KRSA

36.9854.33%
ML

Matthew Leoni

Chief Medical Officer

Dr. Matthew Leoni, also known as Matt, M.D. is Chief Medical Officer of Korsana Biosciences, Inc. from August 2026 and is an accomplished drug developer whose work in early- and late-stage clinical development has contributed to the advancement and approval of multiple innovative therapies over two decades in the biopharmaceutical industry. Dr. Leoni served as Chief Medical Officer of Merida Biosciences from 2024, where he joined following its Series A financing, built the development organization and advanced its lead program through IND clearance and into the clinic. Prior to Merida, he served as Senior Vice President of Development and Biometrics at Cerevel Therapeutics, a company focused on the development of novel therapies for mental and neurological illnesses, where he was a founding member of the company's leadership team in 2019 and helped build it from the ground up, leading it through multiple successful milestone outcomes, clinical milestones, capital formation, its public debut and finally acquisition by AbbVie in August 2024. Earlier in his career, Dr. Leoni held clinical development leadership roles of increasing responsibility including Senior Director, CNS, Global Clinical Development at Otsuka, Novartis, Galderma and Immunomedics. He received his M.D. and medical training from the University of Pennsylvania School of Medicine, his M.B.A. in Pharmaceutical Management from Drexel University and his B.A. in Biology from Franklin & Marshall College.

Positions